Presently, there are no authorized pharmacotherapies for addiction to cocaine and other psychostimulant drugs. Various research have proposed that cannabidiol (CBD) could be a promising remedy for substance use problems. In the present function, the authors describe the scarce preclinical and human analysis about the actions of CBD on the effects of stimulant drugs, primarily cocaine and methamphetamine (METH). On top of that, the probable mechanisms underlying the therapeutic prospective of CBD on stimulant use problems are reviewed. CBD has reversed toxicity and seizures induced by cocaine, behavioural sensitization induced by amphetamines, motivation to self-administer cocaine and METH, context- and anxiety-induced reinstatement of cocaine and priming-induced reinstatement of METH searching for behaviours. CBD also potentiated the extinction of cocaine- and amphetamine-induced conditioned location preference (CPP), impaired the reconsolidation of cocaine CPP and prevented priming-induced reinstatement of METH CPP. Observational research recommend that CBD might minimize complications associated with crack-cocaine addiction, such as withdrawal symptoms, craving, impulsivity and paranoia (Fischer et al., 2015). The prospective mechanisms involved in the protective effects of CBD on addiction to psychostimulant drugs contain the prevention of drug-induced neuroadaptations (neurotransmitter and intracellular signalling pathways modifications), the erasure of aberrant drug-memories, the reversion of cognitive deficits induced by psychostimulant drugs and the alleviation of mental problems comorbid with psychostimulant abuse. Additional, preclinical research and future clinical trials are vital to completely evaluate the prospective of CBD as an intervention for cocaine and methamphetamine addictive problems.